Oxyflora Biotech Profile
Key Indicators
- Authorised Capital ₹ 6.00 M
as on 16-11-2024
- Paid Up Capital ₹ 20.00 K
as on 16-11-2024
- Company Age 3 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.92 Cr
as on 16-11-2024
- Revenue %
(FY 2023)
- Profit -39141.78%
(FY 2023)
- Ebitda -61509.86%
(FY 2023)
- Net Worth -13080.59%
(FY 2023)
- Total Assets 137666.00%
(FY 2023)
About Oxyflora Biotech
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.00 M and a paid-up capital of Rs 20.00 K .
The company currently has active open charges totaling ₹1.92 Cr.
Kamlesh Tyagi and Bhawna Chaudhary serve as directors at the Company.
- CIN/LLPIN
U01100DL2021PTC379978
- Company No.
379978
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Apr 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Oxyflora Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamlesh Tyagi  | Director | 13-Apr-2021 | Current |
| Bhawna Chaudhary | Director | 05-Aug-2021 | Current |
Financial Performance and Corporate Structure Insights of Oxyflora Biotech.
Oxyflora Biotech Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 39141.78% decrease in profit. The company's net worth observed a substantial decline by a decrease of 13080.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oxyflora Biotech?
Unlock access to Oxyflora Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 17 Aug 2024 | ₹0.58 M | Open |
Others Creation Date: 19 Jun 2023 | ₹0.58 M | Open |
Others Creation Date: 25 May 2022 | ₹3.00 M | Open |
How Many Employees Work at Oxyflora Biotech?
Oxyflora Biotech has a workforce of 0 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oxyflora Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oxyflora Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
